Monevue Monevue

Ascendis Pharma A/S
ASND 129.81 Stock Price Ascendis Pharma A/S

Home
  /  
Stock List  /  Ascendis Pharma A/S
Range:90.13-161.0Vol Avg:635493Last Div:0Changes:7.17
Beta:0.65Cap:7.76BCurrency:USDExchange:NASDAQ
Sector:HealthcareIPO:Wed Jan 28 2015Empoloyees:879
CUSIP:04351P101CIK:0001612042ISIN:US04351P1012Country:DK
CEO:Mr. Jan Moller MikkelsenWebsite:https://ascendispharma.com
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Stock Details

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
Positive 0.65

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

seekingalpha.com·Fri Nov 15 2024
Ascendis Pharma Reports Third Quarter 2024 Financial Results
Neutral 0.00

Ascendis Pharma Reports Third Quarter 2024 Financial Results

globenewswire.com·Thu Nov 14 2024
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
Neutral 0.04

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

globenewswire.com·Mon Sep 30 2024
Ascendant Resources Approved for EU Sponsored Cutting-Edge Geophysical "Undercover" Program at Its Lagoa Salgada Project
Positive 0.38

Ascendant Resources Approved for EU Sponsored Cutting-Edge Geophysical "Undercover" Program at Its Lagoa Salgada Project

accesswire.com·Mon Sep 30 2024
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
Neutral 0.10

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

globenewswire.com·Fri Sep 20 2024
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
Neutral 0.10

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

globenewswire.com·Wed Sep 18 2024
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Neutral 0.00

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

zacks.com·Tue Sep 17 2024
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
Positive 0.37

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

zacks.com·Tue Sep 17 2024
Monevue Monevue

About The Monevue

Stock News

Markets

Best Buys

The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection Status • Powered by StackThrow